co-exhibiting companies and partners - lyonbiopôle · 2017-05-31 · co-exhibiting companies and...

FRENCH PAVILION BOOTH N° 3217SAN DIEGO, JUNE 19-22

CO-EXHIBITING COMPANIESAND PARTNERS

CO-EXHIBITING COMPANIES ABL ..................................................................................05

ACCINOV .........................................................................06

ALIZE PHARMA ..............................................................07

ALPHANOSOS S.A.S. ....................................................08

ANS BIOTECH ................................................................09

APTYS PHARMACEUTICALS .......................................10

AVADEL PHARMACEUTICALS .....................................11

BIOASTER .......................................................................12

BIOFILM PHARMA .........................................................13

CARPACCIO ....................................................................14

CEA LETI .........................................................................15

CYTOO .............................................................................16

ENYO PHARMA ..............................................................17

EVEON .............................................................................18

FAB'ENTECH ..................................................................19

GENOWAY .......................................................................20

INDICIA PRODUCTION ..................................................21

INITIATIVE OCTALFA .....................................................22

INNOPAIN .......................................................................23

INOVOTION .....................................................................24

MAAT PHARMA ..............................................................25

NEOLYS DIAGNOSTICS .................................................26

PDC*LINE PHARMA ......................................................27

PREDICTION BIOSCIENCES .........................................28

ROOWIN S.A. ..................................................................29

THERANEXUS ................................................................30

TRANSCURE BIOSERVICES .........................................31

VOXCAN ..........................................................................32

LIFE SCIENCES IN AUVERGNE-RHÔNE-ALPES Lyonbiopole, the gateway to healthcare innovation …………………………………………………………………………………………… 35

Accinov, Biomanufacturing THE OPEN WAY………………………………………………………………………………………………………… 37

Only Lyon, Life Sciences a driving force for Lyon's economy ……………………………………………………………………………… 39

Biopole Clermont Limagne ………………………………………………………………………………………………………………………………… 41

3

TABLE OFCONTENTS

2


WHAT DO ALL CANDIDATE IMMUNOTHERAPIES HAVE IN COMMON? Whether in the preclinical or clinical stage, all immunotherapies need robust and reliable monitoring tools to characterize and track the immune response. ABL’s expertise lies in the monitoring of the immune response within a regulatory compliant setting. We have supported hundreds of preclinical and clinical studies evaluating the safety and efficacy of candidate Monoclonal Antibodies (MAbs), Antibody Drug Conjugates (ADCs), therapeutic vaccines, Chimeric Antigen Receptor T cells (CAR-T cells), and several other novel immunotherapies.

ABL provides its partners with expert immune monitoring solutions. Custom analytical methods are optimized and qualified prior to routine sample testing and are guided by ABL’s decades of experience in immunoassays, flow cytometry, ELISpot and cell-based functional assays.

For more information on our immune monitoring services in the U.S. and Europe, please contact us at: [email protected]

5


ECONOMIC PLAYERS This year in San Diego,

representing the industrial & scientific strengths of the Auvergne-Rhône-Alpes region, under the banner of Lyonbiopole.

28

ABL LYONContact: Nicolas ANFOSSI 321, avenue Jean Jaurès - F - 69007 LYONTel: +33 (0)4 37 70 87 00 / +33 (0)6 47 47 29 73E-mail: [email protected]

www.abl-immuno.com

6 7

Alizé Pharma is a group of companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. Since its creation the group has raised over €18 million from private and institutional investors. The current product portfolio includes the following:

• AZP-531 is a stabilized peptide analog of unacylated ghrelin, a physiological gastrointestinal peptide. This program is in Phase II clinical development for the treatment of Prader-Willi syndrome and has potential in other behavioral, metabolic and ischemia-related indications.

• I-HBD1 program focuses on a new peptide derived from a physiological protein, called IGFBP-2 (Insulin-like Growth Factor Binding Protein-2), as a new bone anabolic agent to be developed in osteoporosis and some rare metabolic diseases associated with impaired bone formation. This I-HBD1 program is at the lead optimization stage.

Accinov, the next-generation biomanufacturing center based in Lyon, proposes a groundbreaking model for running development & GMP manufacturing projects.

Accinov provides biotech, pharma and medtech companies with R&D laboratories, GMP manufacturing pilot units & tailored services, expert advice, guidance and hands-on support for process industrialization & drug development.

Accinov has a pharmaceutical establishment status since end of 2014 and hosts more than 12 companies and projects per year.

For more information: www.accinov.com

ALIZÉ PHARMAContact: Thierry ABRIBAT 15, Chemin du Saquin - BAT G - F - 69130 ECULLYTel: +33 (0)4 72 18 94 28E-mail: [email protected]

www.alz-pharma.com

ACCINOVContact: Stéphanie COLLOUD 317, avenue Jean Jaurès - F - 69007 LYONTel: +33 (0)4 37 28 73 00E-mail: [email protected]

www.accinov.com





8 9

ANS Biotech, a preclinical CRO dedicated to the in vivo pharmacology of pain, offers a unique combination of exceptional expertise in the fundamentals of pain pharmacology and a proven record of R&D program management for the new and innovative analgesics of its clients.

Our mission is to support the drug discovery and development efforts of companies involved in human and animal health, food and nutrition, by offering a broad range of consulting services and a growing list of clinically relevant disease and efficacy models.

As a close Pharma and Biotech partner, ANS Biotech commits itself to providing cost-effective preclinical pharmacology services performed to the highest ethical and quality standards. Our customized scientific studies can help to establish proof of concept & mechanism of action for drug candidates and achieve the critically important positioning of these agents within precise therapeutic categories (neuropathic, bone/joint, visceral, postoperative pain…).

Alphanosos is a French private company (with a US subsidiary in Washington DC) licensing its portfolio of antibiofilm/antibiotic products targeting primarily Staphylococcus aureus (including MRSA/VRSA). These active products are discovered in plants or bacterial extracts using proprietary assays, methods and artificial intelligence algorithms.

Our most active and patented products have been validated in animal models and are available for evaluation under MTA. We also include other patented active discoveries into our proprietary veterinary hygiene and human cosmetic formulations and we are seeking distributors/licensees for them.

We have licensed our first set of antibiofilm products and associated cosmetics to southern Europe companies and are seeking for additional licensees.

ANS BIOTECHContact: François CAUSSADE 20-22, rue Henri et Gilberte Goudier - F - 63200 RIOMTel: +33 (0)9 70 75 85 00E-mail: [email protected]

www.ans-biotech.com

ALPHANOSOS S.A.S. Contact: Laurent LÉOTOING 20-22, rue Henri et Gilberte Goudier - F - 63200 RIOM Tel: +33 (0)9 82 21 65 06E-mail: [email protected]

www.alphanosos.com

αlphanosos



10 11

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Avadel currently markets products in the hospital and primary care spaces.

The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

APTYS is a CRDO (contract research and development organization) which develops innovative products based of its expertise in pharmaceutical technologies and peptide delivery.

Our customers benefit from our know-how and creativity with a strong guarantee of high quality. APTYS offers ISO9001 aligned contract service, according to cGMP.

Skills and know-howCustom-made formulation development including in vivo/in vitro assessments.Semi solid dosage forms for topical and transdermal delivery. Injectable peptide depot formulations. Analytical development and validations. Quality control and ICH stability.

Highlights2003: out-license of a transdermal technology to Ardana Bioscience (UK)2004: development of an inhaled generic product for a big pharma (marketed)2005: out-license a buccal bioadhesive technology to Bioalliance (Loramyc® marketed) 2007: development of an enema for a European pharmaceutical company (marketed)2014: sale of Testocream and Bigel technology to Viramal ltd (phase III)2016: co-development with Unither Pharmaceuticals of an innovative product to treat pain

AVADEL RESEARCHContact: Camille RIVAIL 33, avenue du Dr. Georges Lévy - F - 69200 VENISSIEUXTel: +33 (0)4 72 78 34 34E-mail: [email protected]

www.avadel.com

APTYS PHARMACEUTICALS SAS Contact: François BOUTIGNON Biopôle Clermont Limagne - F - 63360 SAINT BEAUZIRE Tel: +33 (0)4 73 97 06 70E-mail: fb@ aptys-pharmaceuticals.com

www.aptys-pharmaceuticals.com



12 13

BioFilm Pharma brings its innovative approach by addressing the chronic disease and long-term treatment “diabete foot ulcers” (15 million new patients each year), which represent a heavy cost for Health Care system in high-income countries ($4 billions).

BioFilm Pharma holds the unique proprietary technology to develop first-in-class products able to prevent and cure the metastatic bacterial infections named biofilms considered as the new paradigm in the antibiotherapy. We have already 5 compounds in our pipeline and are 3 years up to proof-of-concept in patients for potential blockbusters.

On a first seed round of $3.5 MM, we have already 1.6 M€ from a family Office, and 2 institutional VCs interested. A 2nd round of $25 MM is planned S1 2018 after 1st Lead selection, to expand portfolio and 2 Products Phase II.

BIOASTER was created in April 2012 by the Institut Pasteur and Lyonbiopole health competitiveness cluster, following the initiative of the French government. We have developed a unique technological and innovative model to support the latest challenges in microbiology, in particular to fight antimicrobials resistance, improve vaccines safety and efficacy, quickly diagnose infections at patient bedside and take full advantage of human and animal microbiota.

BIOASTER’s 120 staff members come equally from industries & academics; the large majority are scientists and engineers originating from 17 different citizenships. We drive new technologies innovation in our own infrastructures with state of the art equipment (almost 4,500 m² split between Lyon and Paris, of which 2,500 m² is laboratory space) and privileged access to the French National Physics Computing Centre and the Jean Mérieux BSL4 laboratory in Lyon.

BIOFILM PHARMAContact: Thierry BERNARDI Bâtiment Accinov - 317, avenue Jean JaurèsF - 69007 LYONTel: +33 (0)4 73 33 39 80E-mail: [email protected]

www.biofilmpharma.fr

BIOASTER Contact: Jérémie LANGLET 40, avenue Tony Garnier - F - 69007 LYON Tel: +33 (0)6 16 26 57 29E-mail: [email protected]

www.bioaster.org



14 15

Leti is a technology research institute at CEA Tech. LETI-Health regroups 250 researchers, technicians, engineers and clinicians working in the Technology for Biology and Health Department and Clinatec, a novel pre-clinical and clinical platform developed with the University hospital.

Together with our industrial, clinical and academic partners, we address the following application domains: in vitro diagnostics and monitoring for health, environment, life science, manufacturing and CBRN, therapeutics, nanomedicine and implanted medical devices and imaging systems.

Our core research and development competencies are the development, design, integration and qualification of micro and nanotechnologies, detectors and actuators, imaging technologies, microfluidics, chemistry, biochemistry and electrochemistry, biology, instrumentation including mechanics, software, information processing and electronics. Our strategy is to serve the industry and answer to the health challenges, going toward miniaturization, multi-modality and connected devices, delivering prototypes “ready to transfer”, i.e. compliant with industrial standards and medical regulations.

CARPACCIO.cloud, a "PAY-AS-YOU-GO" online image-analysis service, aims to revolutionize a particularly time-consuming, unattractive and unrewarding step of research: acquiring essential data from microscope images. Currently focusing on muscle, CARPACCIO.cloud aims to become THE reference for analysis of muscle images for CRO’s and research centers worldwide. This, from neuromuscular disease to cancer.

Manual acquisition of essential parameters of 3000 fibers in a muscle image can take two days. CARPACCIO.cloud achieves this automatically, in less than one minute, with close to 100% accuracy and prefect reproducibility. This, via a web interface accessible from any terminal – desktop, laptop, tablet, smartphone - anywhere in the world!

If you are are a public, private, academic, biotech, pharma or clinical research center, performing basic or clinical research, or a CRO performing regulatory studies, you will be amazed at what CARPACCIO.cloud can do for the quality and volume of your throughput.

Accelerate your research ! Think CARPACCIO !

LETIContact: Alexandre THERMET CEA Leti-Health Dpt @ Business France Agency 88 Kearny street, Suite 700CA 94108 SAN FRANCISCO - USTel: +1 (415) 568 4585E-mail: [email protected]

www.leti.fr

CARPACCIO.CLOUDContact: Brian B. RUDKIN c/o PULSALYS - 47 Bd du 11 Novembre 1918F - 69100 VILLEURBANNETel: +33 (0)6 10 28 08 32E-mail: [email protected]

www.carpaccio.cloud



16 17

ENYO Pharma: Drug Discovery Inspired by Viruses

ENYO was founded in 2014 by Inserm scientists, business angels and a seed fund (ITI), joined early 2016 by Sofinnova Partners, InnoBio and Morningside through a Series A of 22 M€.Inspired by the viral adaptation to the human intra-cellular machinery, ENYO develops small molecules modulating host intra-cellular targets primarily for viral diseases but also for other therapeutic areas (e.g. Oncology).

ENYO’s Lead Candidate EYP001 against HBV, Fibrosis and NASH is in PH 1b

The Phase 1a trial (SAD/MAD in Healthy subjects) with its FXR agonist, EYP001, is now completed and the Phase 1b trials in patients infected chronically by the Hepatitis B Virus (HBV) have started. ENYO is also considering entering the Fibrosis and NASH fields with EYP001.

Furthermore, ENYO has recently launched MIMESIS, an upscaling of its platform towards 101 untapped targets with the financial support of the EU Commission.

CYTOO is a preclinical Drug Discovery company addressing muscular disorders. Using its in vitro model of human skeletal muscle (MyoScreen™), CYTOO has developed a first-in-class drug discovery engine for High Throughput and High Content Screening. Through a combination of screening services and sustainable alliances with biopharmaceutical partners, CYTOO brings its R&D platform and lead compounds to discover, profile and develop new effective therapies against muscle wasting (sarcopenia, cachexia) and genetic myopathies (in particular, DMD).

CYTOO also offers early stage drug discovery capabilities in the field of skin disorders. Skin inflammation models derived from the EpiScreen™ micro-epidermis platform are developed to screen, identify and profile new molecular entities active against Psoriasis and Atopic Dermatitis.

These muscle and skin models are already used by the pharmaceutical, dermato-cosmetic, nutraceutical, food processing and animal health sectors for screening of biologically active compounds.

ENYO PHARMA SAContact: Jacky VONDERSCHER Bâtiment Domilyon - 321, Avenue Jean Jaurès F - 69007 LYONTel: +33 (0)4 37 70 02 19E-mail: [email protected]

www.enyopharma.com

CYTOO Contact: Christophe POQUET 7, Parvis Louis Néel - CS 20050F - 38040 GRENOBLE cedex 9 Tel: +33 (0)6 47 27 33 81E-mail: [email protected]

www.cytoo.com



18 19

Fab’entech is a biopharma SME created in 2009 and based in Lyon (France), which is dedicated to the development of specific polyclonal immunotherapies.

It owns a pipeline focused on antitoxin, bioterrorism & infectious disease indications, which is based on a fully-derisked horse F(ab’)2 platform in-licensed from Sanofi Pasteur.

Fab’entech is currently seeking partners to initiate R&D collaborations in new indications, as well as investors to close a Series B fundraising by Q4 2017.

EVEON specializes in smart medical devices for safe, automatic preparation and delivery of drugs. The medical devices developed ensure that the delivered treatment is standardized, controlled, precise. They guaranty comfort and efficacy for patients and health professionals, at home and in medical environments.

Thanks to its unique technology platform Intuity®, EVEON offers several families of medical device in oncology, immunology, hematology,… Protected by 13 patent families, EVEON medical devices are tailor-made for its customers and users.

EVEON, ISO 13485 and ISO 9001 accredited company, has received many awards: • In 2016 and 2017, Pharmapack Europe Award Best Innovation Exhibitor, with special mentions

“Convenience and Ease of use” in February 2016. (Intuity® Mix) and “Ease of use and Patient Compliance” in February 2017 (Intuity® Ject).

• 2nd prize from Alliance for Medical and Biological Engineering) in July 2015.

FAB’ENTECHContact: Raphaël METROP 24, rue Jean Baldassini - F - 69007 LYONTel: +33 (0)4 37 70 75 52E-mail: [email protected]

www.fabentech.com

EVEON Contact: Valérie ROUX-JALLET 345, rue Lavoisier - InovalléeF - 38330 MONTBONNOT SAINT MARTIN Tel: +33 (0)4 76 44 84 17E-mail: [email protected]

www.eveon.eu



20 21

Indicia Production, a Contract Manufacturing Organization, offers industrial production capabilities to Life Science companies wishing to outsource their formulation, filling and sterilization of liquid sterile excipients, culture media or reagents under GMP environment.

Through its recently acquired subsidiary METIS Biotechnologies, Indicia also provides complete systems based on flow cytometry dedicated to the follow up of bioreactor/fermentor processes, providing information about metabolic activity and viability of protein-expressing cells or bacteria within one hour.

Indicia’s technology also permits to count microorganisms in technical waters with a sensitivity of 20-100 cells/ml.

genOway designs and develops accurate in vivo and in vitro preclinical models for target validation, compound efficacy assessment and safety studies. The company holds exclusive intellectual property on key technologies for model creation and provides access to more than 16,000 Knockout and reporter mouse models of target validation.

14 of the Top 20 Pharmas use our services and benefit from our strong scientific input in preclinical models conception, development and management of complex projects. Combining our unrivaled scientific expertise with a robust production platform, the focus of genOway is to provide pharmaceutical companies highly relevant and physiological models within the shortest timelines, to speed up preclinical research projects and enhance clinical trial success rates.

Models are provided with all the required Freedom to operate.

INDICIA PRODUCTIONContact: Stéphane LEGASTELOIS ZA La Parliere - F - 69610 ST GENIS L’ARGENTIERE Tel: +33 (0)4 74 72 36 10E-mail: [email protected]

www.indicia.fr

GENOWAY Contact: Kader THIAM 181, avenue Jean Jaurès - F - 69007 LYON Tel: +33 (0)4 37 65 41 00E-mail: [email protected]

www.genoway.com



22 23

The understanding of the mechanisms of pain has significantly improved in the recent decade, but therapeutic innovation has not yet advanced. Morphine and opiate derivatives are still the privileged drugs used despite their negative side effects.

Scientists have studied morphine’s mechanism of action and have separated the antalgic and the side effect, discovering a new target, TREK1 Channel, and developing a NCE specific of this target. This impacting discovery was published in Nature in 2013 after securing 2 patents.

Innopain has exclusive worldwide license of these 2 patents and our mission is to develop non-opioid original analgesics to replace morphine without its side effects.

Our objective is to get the proof of concept with clinical phase II - intravenous and oral, for acute and chronic pain.

INNOPAIN Contact: Jean DEREGNAUCOURT Biopôle Clermont Limagne - F - 63360 SAINT BEAUZIRE Tel: +33 (0)6 29 37 31 97E-mail: [email protected]

www.innopain.com

Initiative OCTALFA (iO) was incepted on the ground of our previous company, OPi, which developed and marketed several products for rare diseases mostly in onco-hematology indications (e.g. Erwinase for Acute Lymphoblastic Leukemia). Since 2007, iO participated and/or setup 14 companies.

Our last venture, ORPHELIA pharma, is a clinical-stage company which develops pediatric drugs in neurology. iO focuses on projects with high unmet needs in the field of pediatric oncology and hematology, neurology and metabolic disorders.

iO's objectives are to identify inventions (from hospital, academia or industry), coordinate R&D studies prior to the inception of a dedicated company, define the strategy, set up the management and fund activities until the market introduction of products.

Our organization is also housing the Fondation Dominique & Tom Alberici, which supports charity projects dedicated to cancer patients and disabled people (http://initiative-octalfa.eu/en/).

INITIATIVE OCTALFAContact: Jeremy BASTIDEspace Europeen - 15, chemin du Saquin - Bat. GF - 69130 ECULLYTel: +33 (0)4 37 49 87 20E-mail: [email protected]

http://initiative-octalfa.eu



24 25

Founded at the end of 2014 and based in Lyon (France), MaaT Pharma is a microbiome–based biotech company revolutionizing and shaping individualized therapies to treat serious diseases linked to dysbiosis.

MaaT Pharma is currently developing its first candidate using its proprietary Fecal Microbiota Transfer Platform for patients suffering from leukemia, bone and joint infections, as these harsh treatments provoke dysbiosis. MaaT Pharma’s revolutionary and rapid approach plays a considerable part in the evolution of individualized treatment therapies.

After a first successful fundraising of €16M, MaaT Pharma is seeking to raise €25M. The team comprises experienced and knowledgeable professionals who are dedicated to become a leader in microbiome protection and the treatment of clinical consequences of dysbiosis.

MAAT PHARMAContact: Hervé AFFAGARD317, avenue Jean JaurèsF - 69007 LYONTel: +33 (0)6 12 64 26 73E-mail: [email protected]

www.maat-pharma.com

INOVOTION is a biotech company which offers you a unique in vivo technology dedicated to oncology efficacy and toxicity assay.

Our Fast, Sensitive, Reliable and Affordable assay will save you time and money, to give you a clear competitive advantage.

This breaking-thought technology, based on chick embryo, provides early analysis of your drug candidates. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process, increases your R&D productivity and reduces its costs. It’s rapid Go/No Go decision with multi-cancer screening capacities.

This next generation of in vivo efficacy and toxicity tests covers fours main aspects:- EFFICACY assays for your anti-cancer treatments- EARLY TOXICITY assays for your drug candidates- TARGET VALIDATION in oncology- MULTI-CANCER SCREENING to (re)positioning your treatment

INOVOTIONContact: Jean VIALLET Biopolis - 5, avenue du Grand SablonF - 38700 LA TRONCHETel: +33 (0)4 76 54 95 12E-mail: [email protected]

www.inovotion.com



26 27

PDC*line Pharma (www.pdc-line-pharma.com) is clinical stage spin-off of the French Blood Bank (EFS) that develops a new class of cancer active immunotherapies based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells (PDC*line) loaded with targeted tumor antigens.

Thanks to the unique features of PDC*line, our cancer immunotherapies are :• more potent than conventional dendritic cell based approaches,• synergistic with anti-PD-1 (preclinical data),• versatile in terms of antigens (mRNAs, retroviruses, peptides…) and genetic engineering,• applicable to a neoantigen based approach,• off-the-shelf and highly scalable.

PDC LINE PHARMAContact: Laurent LEVY 29, avenue des Maquis du GrésivaudanF - 38701 LA TRONCHE Tel: +33 (0)6 34 36 77 47E-mail: [email protected]

www.pdc-line-pharma.com

Among the 2.5 million cancer patients per year (Europe and North America), 30 to 40% of cancer patients will receive none optimal dose of radiation causing severe adverse reactions or none optimal treatment.

Neolys Diagnostics offers the first tests that determine both the tumor and the patient’s radiosensitivity for a personalized, better tolerated and more efficient radiotherapy.

Neolys Diagnostics proposes to radio-oncologists:

1. An ELISA test to identify the patient at risk during a radiotherapy

2. A service for such patient at risk to characterize precisely the therapeutic index for each patient:• Minimum effective dose on the tumor;• Maximum dose tolerated to the patient;• Expected side effects.

NEOLYS DIAGNOSTICSContact: Gilles DEVILLERS 60, avenue Rockefeller - F - 69008 LYON Tel: +33 (0)6 42 98 40 16E-mail: [email protected]

www.neolysdiagnostics.com



28 29

Created in 1997, Roowin is a French company specialized in high added value fine chemistry.

Roowin is focused on supporting its customers and partners from early research phase up to licencing out API in phase II/III by helping them in their projects of creation, optimization and scale up of efficient chemical routes and analytical methods.

Roowin’s team is formed with highly qualified scientific chemists: about 25 people (50% PhDs) working in 2000 m2 of R&D laboratories, kilo-laboratory and pilot plant, equipped with adapted and efficient equipment’s. Roowin’s missions are:• Drug discovery• Custom & NCE synthesis from mg to 50 kg scale• Process Development• GMP synthesis• Analysis on demand• Development and validation of analytical methods• Stress and Stability studies

Our expertise’s fields are:• Carbohydrates• Aromatic• Heterocyclic• Alkaloids• Peptides• Nucleotides• Fine photochemistry• Chiral separation

Prediction BioSciences is a R&D stage biotechnology company located in Lyon. The firm uses innovative blood biomarkers to develop new diagnostic in the field of stroke and cardiovascular diseases where unmet medical needs are faced. It has a deep diagnostic pipeline which benefits from strong IP protection.

Prediction BioSciences also built partnership with a firm specialized in development and manufacturing to develop a biosimilar drug in the field of stroke, for which phase I in healthy volunteers will be launched in 2018.

The goal of the Company is to develop and bring to clinical phase or market appropriate R&D solutions in the field of stroke, cardiovascular or neurodegenerative diseases (diagnostic or therapeutics).

ROOWIN S.A Contact: Patrice ROOL20, rue Henri Goudier - ZI La Varenne - F - 63200 RIOM Tel: +33 (0)4 73 64 66 00E-mail: [email protected]

www.roowin.fr

PREDICTION BIOSCIENCESContact: Cornelius DIAMOND60, avenue Rockefeller - F - 69008 LYONTel: +33 (0)6 43 52 10 24E-mail: [email protected]

www.predict.net



30 31

Does your therapeutic strategy target the human immune system?

Using human immune system (HIS) mouse models, TransCure bioServices offers its expertise in preclinical services and know-how in study designs to investigate the efficacy of your therapeutic molecule (NCE, peptide or antibody). Immunotoxicity is also evaluated in these models with a customer oriented approach.TransCure bioServices have established three main HIS platforms for drug profiling by in vivo pharmacology:

- HIV for anti-infectious drug candidates/vaccines- Cancer for immunotherapy- IBD for anti-inflammatory

Other platforms are also available in inflammation and auto-immunity (MS, SLE/Lupus, GvHD). Working in our accredited biosafety BSL3 animal facility, anti-infectious targeting not only HIV but also HBV, HCV or Dengue can also be investigated.

Theranexus’ technology is based on the simple yet powerful idea that one could improve the treatment of CNS disorders by combining a neuron targeting drug with a glia targeting drug.

Based on this rational, Theranexus has developed a screening technology leading to the identification of combinations of marketed drugs, one being a standard of care in the indication while the other is repositioned to modulate glial gap junctions.

The outcome of such combination is a more effective therapeutic with a brand new IP that benefits from the FDA 505(b)(2) pathway.

The company now has 3 combinations in development:

• THN102 for the treatment of narcolepsy and attention deficit & excessive sleepiness in Parkinson's disease (P2 ongoing - PoC obtained in healthy volunteers),

• THN101 for the treatment of neuropathic pain (human PoC study planned in 2018),• THN201 for the treatment of dementia (human PoC study planned in 2018)

TRANSCURE BIOSERVICES SASContact: Patrick NEFBiopark Le Forum 1 et 2 - 260, avenue Marie CurieF - 74160 ARCHAMPSTel: +33 (0)4 56 44 81 21E-mail: [email protected]

www.transcurebioservices.com

THERANEXUS S.AContact: Julien VEYSPépinière Laennec - 60, avenue RockfellerF - 69008 LYONTel: +33 (0)1 46 54 85 57E-mail: [email protected]

www.theranexus.com

32 33

Voxcan is one of the most innovative companies for in-vivo studies, with an expertise in Infectious diseases, Oncology & Musculo-Skeletal disorders.

Our facilities include, in addition to state-of-the-art equipment (500 sqm animal housing facility, surgery blocks, Biosafety level 2 & 3 facilities, flux cytometry) an Imaging Platform (bioluminescence and fluorescence imaging systems, X-ray scanners and micro-scanners). We have developed and characterized several animal models that can be monitored by imaging, thus offering a global offer for anatomical imaging or functional imaging, combined with standard clinical follow-up, histology, qPCR. - Oncology & Immuno-Oncology: Lymphoma, Breast, Lung, Ovary, Non-Small Cell Lung, Colon,

Glioblastoma, Prostate, Pancreas, Liver, Leukemia, Both in Subcutaneous or Orthotopic murine models.

- Infectious Diseases: Bacteria (the ESKAPE group), Viruses, Fungi - Musculoskeletal: osseointegration, OsteoArthrisis, Osteoporosis. - In-vivo Biodistribution by fluorescence

We can design on-demand protocols, or you can benefit from our expertise on available models, from mouse to pig.

As a Service Company, we offer our customers very competitive advantages : reduced timelines, competitive rates, respect of GLP Guidelines, flexibility.

VOXCANContact: Najet BEN SALAH1, avenue bourgelat - F - 69280 MARCY L’ETOILETel: +33 (0)4 78 19 52 36E-mail: [email protected]

www.voxcan.fr

NOTE………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………


3434

A DYNAMIC ECOSYSTEM

LIFESCIENCESIN AUVERGNE- RHÔNE-ALPES

3535

200 MEMBERS4 WORD CLASS LEADERS AS FOUNDERS

180 INNOVATIVE COMPANIES 16 RESEARCH & CLINICAL CENTERS

BOOST your business in Europe

GO GLOBAL and access new markets

INNOVATE in a dynamic ecosystem

SETTLE your company in GMP/GLP facilities

w w w . l y o n b i o p o l e . c o m

FOUNDERS AND BOARD MEMBERS

BOARD MEMBERS

REPRESENTING PUBLIC RESEARCH REPRESENTING PRIVATE COMPANIES

O U R P U B L I C A N D P R I V A T E P A R T N E R S A N D F O U N D E R S

STATE AND LOCAL

SUPPORTSGOVERNMENTS

PARTNERS FOR BIO

C

M

J

CM

MJ

CJ

CMJ

N

RV BIO copie.pdf 2 15/05/2017 14:37:37

B I O M A N U F A C T U R I N G T H E O P E N W A Y

THE BIOMANUFACTURING CENTER FOR BIOTECH & MEDTECH COMPANIES

• Drug discovery • Process development • Cell banking• cGMP production of drug substances & drug products using microbial fermentation or cell culture • Production of class III medical devices• Fill & Finish

LABS & PILOT UNIT AS A SERVICE

cGMP compliance Flexibility Quality assurance

Release of experimental drugs

ACCINOV

HOSTED ACTIVITIES

36w w w . l y o n b i o p o l e . c o m

213 R&D PROJECTS FUNDEDSince 2005

992 M€ of total investment406 M€ public funding 120 marketed

products & services

30 clinical trials

performed

174 patents

RESEARCH & INNOVATION

ECONOMIC DEVELOPMENT

+ 708 M€ OF PRIVATE MONEYRAISED BY LYONBIOPOLE MEMBERSSince 2013

201395 M€

2014271 M€

2015540 M€

2016708 M€

95 NETWORKING & SCIENTIFIC EVENTSORGANISED & CO-ORGANISEDBy Lyonbiopole, in 2016

EUROPE & INTERNATIONAL

105 COMPANIES SUPPORTEDIN 7 MISSIONSAround the world, in 2016

ASIA AMERICAEUROPE

FACILITIES OFFER

BSL2 & BSL3 LABORATORIESBIOMANUFACTURING PILOT UNITS

26 ORGANIZATIONS HOSTED IN 2016

IN 3 FACILITIES

C

M

J

CM

MJ

CJ

CMJ

N

RV BIO copie.pdf 1 15/05/2017 14:37:31

37

LIFE SCIENCES, A DRIVING FORCE FOR LYON’S ECONOMY

Lyon metropolitan area is today one of Europe‘s most dynamic and attractive place in the field of Life Sciences & Health. Lyon Métropole has a wide range of responsibilities, including supporting the urban area‘s economic development with a strong emphasis on Life Sciences & Health. Lyon Métropole is a land of innovation & experimentation actively encouraging technological, organizational and social innovation in business. Lyon has a proven track record as a European city of innovation. A local Life Science Network has been created in 2003 under the initiative of the Lyon Métropole who acts as its coordinator. It gathers all organizations active in the Life Sciences’ field, all the skills required to support the development of Life Sciences and increase the attractiveness of the region. Through its partnership-based approach, the objective of this network is to encourage the setting up, anchoring and development of the Life Sciences & Health businesses in Lyon area. Lyon Métropole is also investing on developing the Biodistrict Lyon, showcase site of research and bio-industries, to enhance Lyon as one of the main worldwide area hosting biotechnologies and health activities.

> Support companies and projects> Develop territory’s attractiveness with Aderly and thanks to the economic and urban project Biodistrict Lyon

LYON MÉTROPOLE HELPS COORDINATE AND DENSIFY THE LIFE SCIENCES ECOSYSTEM ON 5 PRIORITY SECTORS

> Enhance network by organizing Biotuesdays> Contribute to the sector’s outreach through professional events (BIO US/Biovision…)

Neurosciences

Nutrition

Oncology

Infectiology

E-health

38 39

DY

KEEP CONTROL & DO IT YOURSELF

BIOMANUFACTURINGin

I

Clémence LABATLife Sciences DirectorGrand Lyon la métropole20, rue du Lac - BP 3103 - 69399 Lyon Cedex 03Phone: +33(0)4 78 63 42 31 - [email protected] www.business.greaterlyon.com

Spread out over 100 hectares in the south of Gerland, thereis a district with an exceptional concentration of key stakeholders: Biodistrict Lyon, the genuine epicenter of life sciences in Lyon region.

Both a living place and a business district combining industry leaders, SMBs and biotechs, in an advanced scientific and academic environment, Biodistrict Lyon gathers the entire value chain, from science… to life.

2

60 000CLINICAL TRIALSPERFORMEDeach year in the Hospices Civils de Lyon

OVER

1 400

JOBS IN HEALTH &BIOTECHNOLOGIES SECTOR

VACCINEPRODUCTIONCENTER in the world

PUBLIC LABORATORIES

Researchers & Teachers-Researchers

PHD STUDENTS

Source: Acoss-Urssaf 2015 and Insee-Clap 2015

since 2005 in Lyon, by vaccinesand diagnostics companies

billion EUROS INVESTED

168 6 800 5 400

40

43

International Trade Services: helping companies export and grow into global marketContact: Emilie Da Silva - Business Development Manager for Americas - [email protected]

www.lyon-metropole.cci.fr

Auvergne-Rhône-Alpes, the densest biocluster in EuropeContact: Anne Le Bars - Project Manager - [email protected]

www.espaceentreprises.rhonealpes.fr

Invest In LyonContact: Nathalie Laurent - Life Sciences Manager - [email protected]

www.aderly.com

The bio entrepreneurs’ hubContact: Clémence Labat - Life Sciences Project Director - [email protected]

www.business.greaterlyon.com

INVEST IN LYONGREATER LYON

CCI OF LYON

PART-NERS

I Nutrition-Health Pharmaceutical

Cosmetics

P

Ô Biotechnologies Green chemistry

Health-Beauty-Fitness Biomedical

Éditi

on 2

017

© L

yonb

iopô

le -

Réa

lisat

ion:

GO

PÉ

APP STORE GOOGLE PLAY STORE

DOWNLOAD LYONBIOPOLE’S APP...

... and keep in touch with our communityMore than 530 contacts

HEALTHCAREINSTITUTIONS

COMPANIES & START-UP

CONSULTANTS &SERVICE PROVIDERS

R&DPROJECTS

RESEARCHUNITS

CLINICAL RESEARCHORGANISATIONS

SUPPORTED BY

C

M

J

CM

MJ

CJ

CMJ

N

Der de couv - Doc BIO copie.pdf 1 15/05/2017 15:42:02

co-exhibiting companies and partners - lyonbiopôle · 2017-05-31 · co-exhibiting companies and...

Documents